Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim N01 in the Treatment of Refractory Chemoradiotherapy-induced Aplastic Anemia
NCT07532408Phase 2Withdrawn
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jun 2026
- Primary completion
- Dec 2028
- Modality
- Recombinant Proteins and Enzymes
01
Overview
A Phase 2 trial of romiplostim in aplastic anemia, sponsored by Peking Union Medical College Hospital. Planned start Jun 2026; status: withdrawn.
02
Drugs
romiplostim
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on NCT07532408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07532408.